Sanofi (SNY) Long-Term Deferred Tax (2009 - 2026)
Sanofi (SNY) posted Long-Term Deferred Tax of $10.2 billion for Q2 2026, up 1.65% sequentially from $10.0 billion in Q4 2025, and up 12.37% YoY from $9.1 billion in Q2 2025.
Sanofi (SNY) Long-Term Deferred Tax (2009 - 2026) Analysis & Trends
Sanofi has reported Long-Term Deferred Tax for 18 years, with the latest figure at $10.2 billion in Q2 2026.
- Quarterly Long-Term Deferred Tax rose 12.37% year-over-year to $10.2 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $10.2 billion (up 12.37% YoY) and the FY2025 annual result came in at $10.0 billion, up 17.7% from the prior year.
- Long-Term Deferred Tax advanced to $10.2 billion in Q2 2026 per SNY's latest filing, from $10.0 billion in the prior quarter.
- Over five years, Long-Term Deferred Tax peaked at $10.2 billion in Q2 2026 and troughed at $5.1 billion in Q2 2022.
- A 5-year average of $7.7 billion and a median of $7.8 billion in 2024 frame the typical range for Long-Term Deferred Tax.
- The sharpest annual moves came in 2022 and 2023: Long-Term Deferred Tax gained 0.23% in 2022, then increased 27.24% in 2023.
- Over 5 years, Long-Term Deferred Tax stood at $5.5 billion in 2022, then grew by 25.96% to $6.9 billion in 2023, then advanced by 23.12% to $8.5 billion in 2024, then rose by 17.7% to $10.0 billion in 2025, then climbed by 1.65% to $10.2 billion in 2026.
- According to Business Quant data, Long-Term Deferred Tax over the past three periods registered $10.2 billion, $10.0 billion, and $9.1 billion for Q2 2026, Q4 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10.19 Bn |
| Dec 31, 2025 | 10.02 Bn |
| Jun 30, 2025 | 9.06 Bn |
| Dec 31, 2024 | 8.51 Bn |
| Jun 30, 2024 | 7.84 Bn |
| Dec 31, 2023 | 6.92 Bn |
| Jun 30, 2023 | 6.51 Bn |
| Dec 31, 2022 | 5.49 Bn |
| Jun 30, 2022 | 5.12 Bn |
| Dec 31, 2021 | 5.26 Bn |
| Jun 30, 2021 | 5.11 Bn |
| Dec 31, 2020 | 4.98 Bn |
| Jun 30, 2020 | 5.32 Bn |
| Dec 31, 2019 | 28.34 Mn |
| Jun 30, 2019 | 5.77 Bn |
| Dec 31, 2018 | 5.27 Bn |
| Sep 30, 2018 | 96.54 Mn |
| Jun 30, 2018 | 25.06 Mn |
| Mar 31, 2018 | 5.21 Bn |
| Dec 31, 2017 | 5.05 Bn |